Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies

BACKGROUND: Psoriatic arthritis (PsA) is a chronic, systemic immune‐mediated inflammatory musculoskeletal disease. The onset of dermatologic symptoms often precedes rheumatic manifestations. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA that has been shown to improve dermato...

Descripción completa

Detalles Bibliográficos
Autores principales: Merola, J.F., Papp, K.A., Nash, P., Gratacós, J., Boehncke, W.H., Thaçi, D., Graham, D., Hsu, M‐A., Wang, C., Wu, J., Young, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818414/
https://www.ncbi.nlm.nih.gov/pubmed/32271970
http://dx.doi.org/10.1111/jdv.16433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818414/
https://www.ncbi.nlm.nih.gov/pubmed/32271970
http://dx.doi.org/10.1111/jdv.16433

Ejemplares similares